Benefits and risks of torasemide in congestive heart failure and essential hypertension.

doi:10.2165/00002018-199614020-00005

Paper

Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Published Feb 1, 1996 · Brater Dc

Drug Safety

Q1 SJR score

27

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Torasemide is a lipophilic anilinopyridine sulphonylurea derivative that acts as a high ceiling loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and hypertension. Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action; namely, blockade of Na+/K+/2Cl− cotransport in the thick ascending limb of the loop of Henle. It has high bioavailability (>80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide).

Study Snapshot

Torasemide is a high-dose loop diuretic with a longer elimination half-life, making it a potential treatment option for congestive heart failure and essential hypertension.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Sign up to use Study Snapshot

References

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure

Torsemide is more rapidly absorbed and has greater bioavailability than furosemide in patients with congestive heart failure, but both diuretic agents show decreased nephron response compared to healthy subjects.

Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide.

Food intake affects the absorption rate of torsemide, but the diuretic effect remains consistent regardless of food intake.

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.

Human hepatic CYP2C9 is the predominant enzyme responsible for the rate-limiting step in torsemide metabolism, potentially impacting its clearance in patients.

Intravenous Torsemide as Adjunctive Therapy in Patients with Acute Pulmonary Edema

Intravenous torsemide is an effective and well-tolerated diuretic for patients with acute cardiogenic pulmonary edema, improving pulmonary rales and orthopnea without serious adverse events.

Diuretic treatment for the sodium retention of congestive heart failure.

Diuretics are a mainstay for treating sodium retention in congestive heart failure, but large clinical trials are needed to confirm their effectiveness without adverse effects like electrolyte depletion and increased mortality.

Citations

Safety of torasemide in healthy adult dogs administered daily for 26 weeks

Torasemide is safe for dogs when administered at 0.25 mg/kg once daily for 26 weeks, with any changes consistent with its known diuretic effects.

Torasemide versus furosemide in treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.

Torasemide has potential advantages in heart failure management, including lower hospital stay and improved ejection fraction, compared to furosemide.

Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology

Torasemide may have advantages on NYHA class and long-term outcomes in heart failure patients, especially in younger patients or those with dilated cardiomyopathy, but further investigations are needed.

Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy

Torasemide treatment effectively protects against adverse cardiac remodeling in chronic heart failure rats, offering better protection than spironolactone.

Comparative effects of torasemide and furosemide on gap junction proteins and cardiac fibrosis in a rat model of dilated cardiomyopathy

Torasemide treatment has a superior anti-fibrotic effect in hearts of chronic heart failure rats, potentially through improving gap junction protein expression and enhancing cell-cell interaction.